MARSEILLE, France / Nov 17, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its executive team will participate in one-on-one meetings and present on Monday, November 17, 2025. Jefferies Global Healthcare Conference Date: November 17, 2025 Time:... Read More

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of € 56.4 million 1 as of September 30, 2025, anticipated cash... Read More

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of systemic therapy. The Company submitted the confirmatory Phase 3 TELLOMAK 3 protocol to the FDA, which completed its review with no further comments, clearing the study to proceed. The Company is progressing towards the initiation... Read More

MARSEILLE, France / Nov 05, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer... Read More

The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation Leading KOL Pierluigi Porcu, M.D., a world expert in T-cell lymphomas, will discuss results from the TELLOMAK Phase 2 trial ZS Associates, leading experts in life sciences and healthcare markets, will describe the eligible... Read More

IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol... Read More

MARSEILLE, France / Sep 15, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25 th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France. The European Midcap Event is a key gathering that brings... Read More

MARSEILLE, France / Sep 10, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive... Read More

MARSEILLE, France / Sep 02, 2025 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

MARSEILLE, France / Aug 04, 2025 / Business Wire / Regulatory news: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

MARSEILLE, France / Jul 29, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking, institutional trading,... Read More

MARSEILLE, France / Jul 04, 2025 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as of July 3,... Read More

MARSEILLE, France / Jun 17, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed below. H.C. Wainwright 3 rd Annual Immune Cell Engager Virtual Conference Dates: June 24, 2025 | Virtual Wolfe Research Virtual Biotech Day Dates: June 26, 2025... Read More

Preclinical data from IPH6501, Innate’s proprietary ANKET ® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), will be presented Preclinical in vivo models support enhanced antitumor efficacy for the combination of IPH6501 with R-CHOP, the standard of care in untreated DLBCL and FL patients IPH6501 is currently... Read More

MARSEILLE, France / May 27, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below. Jefferies Global Healthcare Conference Dates: June 3 – 5 2025 | New York, USA The executive team will participate in a fireside chat... Read More

MARSEILLE, France / May 23, 2025 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted. A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43,535,215 voting rights, representing a... Read More

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from TELLOMAK study confirms the meaningful clinical activity in heavily pretreated SS patients with a global overall response rate (ORR) of 42.9% and an impressive median duration of response of 25.6 months.​ Data also confirms meaningful... Read More

Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides Trial in Progress poster on IPH4502, Innate’s differentiated ADC in development in advanced solid tumors expressing Nectin-4 AstraZeneca to present a poster on updated results from the Phase 2 trial NeoCOAST-2 in resectable NSCLC MARSEILLE, France / May 19, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris:... Read More

MARSEILLE, France / May 15, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract regarding IPH6501, its ANKET ® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan,... Read More

€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET ® program in autoimmune indications First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory... Read More

MARSEILLE, France / May 12, 2025 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

MARSEILLE, France / May 06, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025. In addition, members of the executive management team will be meeting with investors... Read More

MARSEILLE, France / Apr 30, 2025 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2024 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“ AMF ”) on April 30, 2025. It can be downloaded (in French) on the... Read More

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV. IPH4502 showed strong preclinical activity across multiple tumor types,... Read More

MARSEILLE, France / Apr 28, 2025 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET ® program in autoimmune indications, and more MARSEILLE, France / Apr 24, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April... Read More

Innate to regain its rights on CD123 targeting ANKET ® SAR443579 (SAR’579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions Sanofi to continue development of BCMA targeting ANKET ® program in autoimmune indications Innate still eligible for more than €1 billion R&D and commercial milestones MARSEILLE, France / Apr... Read More

Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the... Read More

MARSEILLE, France / Apr 16, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its annual general meeting of shareholders (“ AGM ”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille. The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bulletin. It includes the... Read More

MARSEILLE, France / Apr 03, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025. The executive team will participate in a fireside chat scheduled on Wednesday, April 9, 2025, from 12:30... Read More

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024 The first patient was dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors IPH6501, Innate's proprietary... Read More

IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Nectin-4 expression, extending its potential beyond urothelial carcinoma. Jonathan Dickinson, CEO of Innate, to... Read More

MARSEILLE, France / Mar 25, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below: Life Sciences Van Lanschot Kempen Conference Event dates: April 1 – 3, 2025 | Amsterdam, Netherlands About Innate Pharma Innate Pharma S.A. is... Read More

MARSEILLE, France / Mar 20, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024. Participants during the call will be: Jonathan Dickinson, Chief... Read More

MARSEILLE, France / Feb 27, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on March 10 – 12, 2025 in W Hotel South Beach in Miami, Florida. The executive team will participate in a fireside chat... Read More

Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab. Breakthrough Therapy Designation is intended to accelerate the development and regulatory review in the U.S. of drugs that are intended to treat a serious condition; adding to a Fast Track designation by the U.S. FDA received in 2019 as well... Read More

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 MARSEILLE, France / Jan 27, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first patient was dosed in its Phase 1 study ( NCT06781983 ), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug... Read More

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage MARSEILLE, France / Jan 21, 2025 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its... Read More

MARSEILLE, France / Jan 16, 2025 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET ® NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage assets through partnerships MARSEILLE, France / Jan 10, 2025 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”)... Read More

MARSEILLE, France / Dec 20, 2024 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that its management will present and host 1x1 meetings at the 43 rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled... Read More

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas MARSEILLE, France / Dec 09, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL)... Read More

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial investigating IPH6501 in patients with R/R CD20+ Non-Hodgkin Lymphoma MARSEILLE, France & DIAMOND BAR, Calif. / Dec 06, 2024 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq:... Read More

MARSEILLE, France / Dec 03, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET ® asset, have been selected for the American Society of hematology (ASH) Annual Meeting. “ We are proud of... Read More

MARSEILLE, France / Nov 20, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2025 financial calendar: March 27, 2025 : Publication of 2024 financial statements May 13, 2025 : Publication of revenue and cash position for 1Q2025 May 22, 2025 : Annual General Shareholders Meeting September 17, 2025 : Publication of half year financial... Read More

IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to... Read More

Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell... Read More

MARSEILLE, France / Nov 08, 2024 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate ( ADC) and innovative tetra-specific ANKET ® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at... Read More

MARSEILLE, France / Nov 07, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer... Read More

MARSEILLE, France / Oct 29, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team are scheduled to participate in the upcoming investor conferences, detailed below. Stifel Healthcare Conference Event dates: November 18 – 19, 2024 | New York, United States Jefferies London Healthcare Conference Event... Read More

Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition MARSEILLE, France / Oct 14, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that its supervisory Board has appointed Jonathan Dickinson... Read More

MARSEILLE, France / Sep 30, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will co-host with the Icahn School of Medicine at Mount Sinai a scientific symposium entitled “ Next Generation Immunotherapy Discoveries ”. The symposium will be held in a hybrid format on Thursday, October 3, 2024, from 10:00 a.m. to 5:30 p.m. EDT at the Hess Center for... Read More

IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 MARSEILLE, France / Sep 23, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical... Read More

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH6101 1 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study Updated data from dose-escalation part presented at EHA 2024 confirm clinical benefit and durable responses in patients with R/R AML IPH45, proprietary anti Nectin-4 ADC progressing... Read More

MARSEILLE, France / Sep 09, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 ( NCT05061550 ) Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8, 2024. The NeoCOAST-2 platform study is intended to assess... Read More

MARSEILLE, France / Sep 05, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer... Read More

MARSEILLE, France / Sep 04, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming investor conference, detailed below. H.C. Wainwright 26th Annual Global Investment Conference Date: September 10, 2024 | New York, United States About Innate Pharma Innate... Read More

MARSEILLE, France / Aug 01, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conference, detailed below. Participants will include Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations. BTIG Virtual Biotechnology Conference... Read More

MARSEILLE, France / Jul 25, 2024 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

MARSEILLE, France / Jun 18, 2024 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues to show clinical benefit and durable responses along with a favorable safety profile in patients with R/R AML, with 5 complete remissions (4 CR / 1 CRi)... Read More

In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL event on Tuesday, June 11, 2024 at 4:00PM CEST (10:00AM EDT). MARSEILLE, France / Jun 04, 2024 / Business Wire / Regulatory News: Innate Pharma... Read More

MARSEILLE, France / May 28, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé Brailly, Chief Executive Officer, Sonia Quaratino, Executive Vice President (EVP), Chief Medical Officer, Yannis Morel,... Read More

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET ® , for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 MOZART trial poster... Read More

MARSEILLE, France / May 23, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23, 2024, in Marseille. All resolutions were voted. A total of 84 votes were cast out of a total of 36,317,268 shares giving right to 36,798,714 voting rights,... Read More

MARSEILLE, France / May 21, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast... Read More

Two abstracts on SAR443579 (IPH6101), ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate’s second generation ANKET ® for the treatment of relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphomas MARSEILLE, France / May 15, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris:... Read More

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides Two posters on IPH6501, Innate's second generation ANKET ® in B‑cell Non-Hodgkin's Lymphoma... Read More

MARSEILLE, France / May 07, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia... Read More

MARSEILLE, France / Apr 15, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Notice of Meeting of this AGM was published on April 15, 2024 in the French legal bulletin. It includes the... Read More

Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone payment to Innate MARSEILLE, France / Apr 15, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the... Read More

IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Preclinical efficacy and toxicology data support further development of IPH45 which is progressing towards the clinic with IND planned in 2024 MARSEILLE,... Read More

MARSEILLE, France / Apr 09, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Van Lanschot Kempen conference Event Date: April 16-17, 2024 | Amsterdam, Netherlands About Innate Pharma Innate Pharma S.A. is a global,... Read More

MARSEILLE, France / Apr 05, 2024 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2023 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“ AMF ”) on April 4, 2024. It can be downloaded (in French) on the... Read More

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress Licensing of a fourth NK cell engager ANKET ® by Sanofi, triggering a €15m payment to Innate; ANKET ® partnered assets progressing well with two molecules in clinical trials First patient dosed in Phase 1/2 clinical trial with IPH6501,... Read More

MARSEILLE, France / Mar 19, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating... Read More

MARSEILLE, France / Mar 14, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023. Participants during the call will be: Hervé Brailly, Chief... Read More

IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IPH45, a differentiated topoisomerase I inhibitor ADC targeting Nectin-4, which is progressing towards the clinic MARSEILLE, France / Mar 06, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract... Read More

Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET ® platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas. MARSEILLE, France / Mar 06, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first patient was dosed in its Phase 1/2... Read More

MARSEILLE, France / Feb 21, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below. Leerink Partners Global Biopharma Conference 2024 Event Date: March 11-13, 2024, Miami, Florida About Innate Pharma Innate Pharma S.A.... Read More

MARSEILLE, France / Jan 12, 2024 / Business Wire / Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights... Read More

FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment MARSEILLE, France / Jan 04, 2024 / Business Wire / Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND. On... Read More

Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board MARSEILLE, France / Jan 04, 2024 / Business Wire / Regulatory News: Innate... Read More

Sanofi to exercise one option to license a new ANKET ® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the program Innate to receive €15m as option exercise payment Regulatory News MARSEILLE, France / Dec 19, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today... Read More

Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chairman of the Supervisory Board, former CEO and company co-founder Hervé Brailly appointed interim CEO Irina Staatz-Granzer, current Vice-Chairwoman of Supervisory Board, appointed Chairwoman of the Supervisory Board MARSEILLE, France / Dec 18, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH;... Read More

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R AML with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, and was well tolerated up to doses of 6 mg/kg SAR443579 demonstrated durable responses... Read More

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) MARSEILLE, France / Dec 10, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced positive final results... Read More

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) MARSEILLE, France / Nov 27, 2023 / Business Wire / Innate Pharma SA... Read More

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH Annual Meeting 2023 ASH presentation on SAR443579/IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; the ANKET ® platform lead asset and under development by partner Sanofi, which demonstrated... Read More

MARSEILLE, France / Nov 07, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Yannis Morel,... Read More

Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with peripheral T-cell lymphoma Presentation on SAR443579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123;... Read More

MARSEILLE, France / Oct 27, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Conference Event Date: November 15, 2023, London, UK 6th Annual Evercore ISI HealthCONx Conference Event Date: November 28,... Read More

MARSEILLE, France / Oct 19, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024: Publication of revenue for 1Q2024 May 23, 2024: Annual General Shareholders Meeting September 12, 2024: Publication of half year financial statements November 13, 2024:... Read More

Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation Presentations under the AstraZeneca collaboration include an IPH5201 early lung cancer Trial in Progress poster and monalizumab SCCHN updates MARSEILLE, France / Oct 16, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the following... Read More

MARSEILLE, France / Oct 09, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at October 3,... Read More

Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023 Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023 US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction MARSEILLE, France / Oct 05, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today... Read More

Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides Updated global ORR of 42.9% in heavily pretreated KIR3DL2-expressing patients with Mycosis Fungoides MARSEILLE, France / Sep 22, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today... Read More

Phase 1/2 dose escalation safety and preliminary efficacy of ANKET ® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; $5m upfront... Read More

MARSEILLE, France / Aug 29, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress... Read More

MARSEILLE, France / Aug 10, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming conference: H.C. Wainwright Immune Cell Engager Virtual Conference Event Date: August 17 - virtual About Innate Pharma Innate Pharma S.A. is a global, clinical-stage... Read More

Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) Second molecule from Innate’s multi-specific NK cell engager platform ANKET ® to progress to the clinic MARSEILLE, France /... Read More

MARSEILLE, France / Jul 07, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at July 1,... Read More

Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE, France / Jun 26, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the first patient was dosed in MATISSE, a Phase... Read More

Efficacy results presented at the 17th International Conference on Malignant Lymphoma, have been analysed according to updated lymph node involvement classification and confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides Updated global ORR of 42.9% in heavily pretreated KIR3DL2-expressing patients with Mycosis Fungoides MARSEILLE, France / Jun 16, 2023 / Business Wire / Innate... Read More

Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France / Jun 12, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will... Read More

IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET ® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas IPH6501 is progressing towards a Phase 1 clinical trial in 2023 MARSEILLE, France / Jun 10, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that... Read More

SAR’579, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi. MARSEILLE, France / Jun 08, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) is pleased to share Sanofi’s news that the U.S. Food and Drug Administration (FDA) has... Read More

MARSEILLE, France / Jun 07, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at June 1,... Read More

SAR’579/IPH6101, ANKET ® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published show SAR’579 was well tolerated and induced 3 complete responses in the 8 patients at 1 mg/kg as highest dose Phase 1/2 data will be presented as an oral presentation at the ASCO 2023... Read More

MARSEILLE, France / May 23, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming conferences: American Society for Clinical Oncology (ASCO) 2023 Annual Meeting Event Date: June 2-5, Chicago (USA) Jefferies Healthcare Conference 2023 Event Date: June 7-9,... Read More

IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation MARSEILLE, France / May 15, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET ® ( A ntibody-based N... Read More

MARSEILLE, France / May 12, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 12, 2023, in Marseille. All resolutions were voted. A total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum... Read More

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to up to $410m in future milestones plus royalties ANKET ® assets in collaboration with Sanofi continue to progress; abstract for IPH6101/SAR’579 selected for oral presentation at ASCO 2023 annual meeting Cash position of €135.0... Read More

MARSEILLE, France / May 03, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel,... Read More

Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR’579 / IPH6101 is ANKET ® platform lead asset and under development by partner Sanofi Two Trial in Progress posters including monalizumab in non-small cell lung cancer, developed in collaboration with AstraZeneca MARSEILLE, France / May 03, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH;... Read More

MARSEILLE, France / Apr 26, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to a new At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75... Read More

MARSEILLE, France / Apr 18, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at April 1,... Read More

The Annual General Meeting will be broadcasted live by the Company MARSEILLE, France / Apr 07, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 12, 2023 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Annual General Meeting will be broadcasted live. The Notice... Read More

MARSEILLE, France / Apr 06, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2022 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” (“ AMF ”) on April 6, 2023. It can be downloaded (in French) on the... Read More

Takeda to obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate MARSEILLE, France / Apr 03, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to... Read More

Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET ® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash... Read More

MARSEILLE, France / Mar 20, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at March 1,... Read More

MARSEILLE, France / Mar 16, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson... Read More

MARSEILLE, France / Mar 13, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. None of Innate Pharma’s cash and cash equivalents are held through Silicon Valley Bank and... Read More

MARSEILLE, France / Feb 21, 2023 / Business Wire / Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at February... Read More

MARSEILLE, France / Feb 07, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences: SVB Securities Global Biopharma Conference Event Date: February 14 - 16, 2023 (virtual) Citi's 2023 Virtual Oncology Leadership Summit Event Date: February... Read More

Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. MARSEILLE, France / Jan 25, 2023 / Business Wire / Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust... Read More

Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by Sanofi is ongoing Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML)... Read More

Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKET TM (Antibody-based NK cell Engager Therapeutics) platform on display at ASH via oral presentation and posters MARSEILLE, France--( BUSINESS WIRE )--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “... Read More